Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009232 | 0.78 | RAD52 (0.39) | TDP2RAB9ANPC1HRH4MAPT | |
| SCHEMBL12759458 | 0.78 | TDP2 (0.49) | TDP2RAB9AHSD17B2NPC1NR1H2 | |
| SCHEMBL11553734 | 0.73 | TDP2 (0.53) | TDP2RAB9AHSD17B2NPC1NR1H2 | |
| SCHEMBL26251829 | 0.72 | TLR8 (0.46) | RAB9ANPC1KDM4EALDH1A1TP53 | |
| SCHEMBL25817338 | 0.71 | RAB9A (0.58) | RAB9ANPC1HRH4TP53SMN1; SMN2 | |
| SCHEMBL25762600 | 0.71 | RAB9A (0.58) | RAB9ANPC1HRH4TP53SMN1; SMN2 | |
| SCHEMBL3766697 | 0.71 | RAB9A (0.73) | RAB9ANPC1HRH4TP53SMN1; SMN2 | |
| SCHEMBL4546968 | 0.69 | RAB9A (0.70) | RAB9ANPC1HRH4TP53SMN1; SMN2 | |
| SCHEMBL25599752 | 0.69 | NR1H2 (0.71) | TDP2RAB9AHSD17B2NPC1NR1H2 | |
| SCHEMBL17279740 | 0.68 | NR1H3 (0.82) | TDP2RAB9AHSD17B2NPC1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | TDP2 684/4885RAB9A 1213/4885HSD17B2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.